Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/08/2012 | 07:44am CEST

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
10:39a SANOFI : Regeneron RA Drug Kevzara Wins FDA Approval
05/23 SANOFI : and Regeneron Announce FDA Approval of Kevzara (Sarilumab) for the Trea..
05/23 THE BUSINESS RESEARCH COMPANY : Asia accounted for $307 billion in the pharmaceu..
05/23 SANOFI : s insulin lispro receives CHMP positive opinion to treat diabetes
05/23 SANOFI : Phony Veterinary Labels Land Michael Chihwen Wang in the Doghouse
05/22 SANOFI : and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Tre..
05/22 SANOFI SA : Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispr..
05/20 SANOFI : Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar
05/20 SANOFI : `s Zika-shot pricing dust-up highlights a divide over taxpayer-backed v..
05/20 Corticosteroids Market 2017 - GSK, Cipla, Sumitomo, Pfizer, Novartis, Merck, ..
More news
Sector news : Pharmaceuticals - NEC
07:35p JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
06:10p FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:29p Exelixis Could Still Be A Buy
12:27p 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 24, 2017 - FDA Makes History
05/23 What Happened With The Genzyme CVR Since August 2015
05/23 Sanofi and Regeneron's RA med Kevzara faces crowded market
05/22 Regeneron, Sanofi rheumatoid arthritis drug wins FDA approval
Advertisement
Financials (€)
Sales 2017 36 717 M
EBIT 2017 9 456 M
Net income 2017 7 526 M
Debt 2017 3 542 M
Yield 2017 3,42%
P/E ratio 2017 14,85
P/E ratio 2018 18,20
EV / Sales 2017 3,11x
EV / Sales 2018 2,98x
Capitalization 110 639 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 85,6 €
Spread / Average Target -2,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI14.93%124 306
JOHNSON & JOHNSON10.46%342 817
ROCHE HOLDING LTD.14.79%237 610
NOVARTIS AG6.28%213 719
PFIZER INC.-1.05%191 279
MERCK & CO., INC.9.65%175 160
More Results